This page is part of our 2023 average annual return archive: it shows the CHRS stock yearly return for calendar year 2023. This metric helps investors evaluate and compare performance among different stocks, over time.
Average annual return should be reviewed alongside overall market trends, and company fundamentals like earnings and revenue. As the saying goes on Wall St., past performance from 2023 does not guarantee future similar returns.
| CHRS Stock Yearly Return 2023 Table | ||||||||||||||||||||||||||||||
CHRS average annual return is presented with the assumption of reinvestments of any dividends on ex-date. |
| Average Annual Return Benchmarks |
|
Compare CHRS average annual return versus benchmarks: S&P Average Annual Return Dow Average Annual Return Nasdaq 100 Average Annual Return Russell 2000 Average Annual Return Gold Average Annual Return 10 Year Treasury Average Annual Return |
| CHRS Share Performance |
| CHRS Stock Yearly Return 2023 Chart | |||
Also see: • CHRS YTD return • CHRS average annual return 10 years | |||
| About Coherus BioSciences Inc |
| Coherus BioSciences is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Co. in-licensed its lead immuno-oncology product candidate, toripalimab (CHS-007), an anti-PD-1 antibody, from Shanghai Junshi Biosciences Co., Ltd. Toripalimab is being evaluated in late-stage clinical trials for the treatment of a range of tumor types. Co.'s commercial portfolio includes two U.S. Food and Drug Administration-approved biologics, including UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, a granulocyte-colony stimulating factor and YUSIMRY™ (adalimumab-aqvh), its Humira® (adalimumab) biosimilar product. The CHRS stock yearly return is shown above.
The yearly return on the CHRS stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2023 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon. One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the CHRS annual return calculation with any dividends reinvested as applicable (on ex-dates). |
| CHRS Current Stock Quote |
 Free CHRS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Don't Forget Dividends in Annual Return! | |
|
| Yearly Return Peers |
| Coherus BioSciences (CHRS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:
CI Average Annual Return |
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.
Video: Don't Forget Dividends in Average Annual Return!